130 related articles for article (PubMed ID: 38548090)
1. Heparan sulfate selectively inhibits the collagenase activity of cathepsin K.
Zhang X; Luo Y; Hao H; Krahn JM; Su G; Dutcher R; Xu Y; Liu J; Pedersen LC; Xu D
Matrix Biol; 2024 May; 129():15-28. PubMed ID: 38548090
[TBL] [Abstract][Full Text] [Related]
2. Heparan sulfate selectively inhibits the collagenase activity of cathepsin K.
Zhang X; Luo Y; Hao H; Krahn JM; Su G; Dutcher R; Xu Y; Liu J; Pedersen LC; Xu D
bioRxiv; 2024 Jan; ():. PubMed ID: 38260317
[TBL] [Abstract][Full Text] [Related]
3. Knockout and Double Knockout of Cathepsin K and Mmp9 reveals a novel function of Cathepsin K as a regulator of osteoclast gene expression and bone homeostasis.
Zhu G; Chen W; Tang CY; McVicar A; Edwards D; Wang J; McConnell M; Yang S; Li Y; Chang Z; Li YP
Int J Biol Sci; 2022; 18(14):5522-5538. PubMed ID: 36147479
[TBL] [Abstract][Full Text] [Related]
4. A composite docking approach for the identification and characterization of ectosteric inhibitors of cathepsin K.
Law S; Panwar P; Li J; Aguda AH; Jamroz A; Guido RVC; Brömme D
PLoS One; 2017; 12(10):e0186869. PubMed ID: 29088253
[TBL] [Abstract][Full Text] [Related]
5. A novel approach to inhibit bone resorption: exosite inhibitors against cathepsin K.
Panwar P; Søe K; Guido RV; Bueno RV; Delaisse JM; Brömme D
Br J Pharmacol; 2016 Jan; 173(2):396-410. PubMed ID: 26562357
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a New Class of Cathepsin K Inhibitors in Rhizoma Drynariae as Potential Candidates for the Treatment of Osteoporosis.
Qiu ZC; Dong XL; Dai Y; Xiao GK; Wang XL; Wong KC; Wong MS; Yao XS
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999266
[No Abstract] [Full Text] [Related]
7. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation.
Lotinun S; Kiviranta R; Matsubara T; Alzate JA; Neff L; Lüth A; Koskivirta I; Kleuser B; Vacher J; Vuorio E; Horne WC; Baron R
J Clin Invest; 2013 Feb; 123(2):666-81. PubMed ID: 23321671
[TBL] [Abstract][Full Text] [Related]
8. Tanshinones that selectively block the collagenase activity of cathepsin K provide a novel class of ectosteric antiresorptive agents for bone.
Panwar P; Law S; Jamroz A; Azizi P; Zhang D; Ciufolini M; Brömme D
Br J Pharmacol; 2018 Mar; 175(6):902-923. PubMed ID: 29278432
[TBL] [Abstract][Full Text] [Related]
9. Not all pycnodysostosis-related mutants of human cathepsin K are inactive - crystal structure and biochemical studies of an active mutant I249T.
Roy S; Das Chakraborty S; Biswas S
FEBS J; 2018 Nov; 285(22):4265-4280. PubMed ID: 30199612
[TBL] [Abstract][Full Text] [Related]
10. AP-1 and Mitf interact with NFATc1 to stimulate cathepsin K promoter activity in osteoclast precursors.
Pang M; Rodríguez-Gonzalez M; Hernandez M; Recinos CC; Seldeen KL; Troen BR
J Cell Biochem; 2019 Aug; 120(8):12382-12392. PubMed ID: 30816596
[TBL] [Abstract][Full Text] [Related]
11. Heparan Sulfate Regulates the Structure and Function of Osteoprotegerin in Osteoclastogenesis.
Li M; Yang S; Xu D
J Biol Chem; 2016 Nov; 291(46):24160-24171. PubMed ID: 27697839
[TBL] [Abstract][Full Text] [Related]
12. The role of basic amino acid surface clusters on the collagenase activity of cathepsin K.
Nallaseth FS; Lecaille F; Li Z; Brömme D
Biochemistry; 2013 Nov; 52(44):7742-52. PubMed ID: 24088021
[TBL] [Abstract][Full Text] [Related]
13. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
14. The silencing of cathepsin K used in gene therapy for periodontal disease reveals the role of cathepsin K in chronic infection and inflammation.
Chen W; Gao B; Hao L; Zhu G; Jules J; MacDougall MJ; Wang J; Han X; Zhou X; Li YP
J Periodontal Res; 2016 Oct; 51(5):647-60. PubMed ID: 26754272
[TBL] [Abstract][Full Text] [Related]
15. The role of cathepsin K in oral and maxillofacial disorders.
Wen X; Yi LZ; Liu F; Wei JH; Xue Y
Oral Dis; 2016 Mar; 22(2):109-15. PubMed ID: 26458004
[TBL] [Abstract][Full Text] [Related]
16. Phlpp1 is induced by estrogen in osteoclasts and its loss in Ctsk-expressing cells does not protect against ovariectomy-induced bone loss.
Hanson MK; Karkache IY; Molstad DHH; Norton AA; Mansky KC; Bradley EW
PLoS One; 2021; 16(6):e0251732. PubMed ID: 34143773
[TBL] [Abstract][Full Text] [Related]
17. Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities.
Wilson S; Hashamiyan S; Clarke L; Saftig P; Mort J; Dejica VM; Brömme D
Am J Pathol; 2009 Nov; 175(5):2053-62. PubMed ID: 19834056
[TBL] [Abstract][Full Text] [Related]
18. Structural requirements for the collagenase and elastase activity of cathepsin K and its selective inhibition by an exosite inhibitor.
Sharma V; Panwar P; O'Donoghue AJ; Cui H; Guido RV; Craik CS; Brömme D
Biochem J; 2015 Jan; 465(1):163-73. PubMed ID: 25279554
[TBL] [Abstract][Full Text] [Related]
19. Preservation of type H vessels and osteoblasts by enhanced preosteoclast platelet-derived growth factor type BB attenuates glucocorticoid-induced osteoporosis in growing mice.
Yang P; Lv S; Wang Y; Peng Y; Ye Z; Xia Z; Ding G; Cao X; Crane JL
Bone; 2018 Sep; 114():1-13. PubMed ID: 29800693
[TBL] [Abstract][Full Text] [Related]
20. Antiresorptive activity of osteoprotegerin requires an intact heparan sulfate-binding site.
Li M; Xu D
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17187-17194. PubMed ID: 32636266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
